Gammanorm

DRUG4 trials

Sponsors

Universitair Medisch Centrum Utrecht, Octapharma

Conditions

Autoimmune DiseasesPrimary Immunodeficiency (PID)Primary antibody deficiency: - Unclassified antibody deficiency (unPAD) - IgA deficiency - Specific polysaccharide antibody deficiency (SPAD) - IgG subclass deficiency (IgSD) - Common variable immunodeficiency (CVID) - Agammaglobulinemia (X-linked or otherwise)Secondary Immune Deficiency

Phase 3

Influencing Progression of Airway Disease in Primary Antibody Deficiency

Not yet recruitingCTIS2024-513124-41-00

Universitair Medisch Centrum UtrechtPrimary antibody deficiency: - Unclassified antibody deficiency (unPAD) - IgA deficiency - Specific polysaccharide antibody deficiency (SPAD) - IgG subclass deficiency (IgSD) - Common variable immunodeficiency (CVID) - Agammaglobulinemia (X-linked or otherwise)

Target: 100Updated: 2024-07-12

Phase 4

Gammanorm Quality of Life Study in Immunodeficient Patients Using Rapid Push or Pumps

CompletedNCT02180763

OctapharmaPrimary Immunodeficiency (PID)

Start: 2014-04-30End: 2017-08-26Updated: 2018-09-05

Unknown Phase

The Effect of Subcutaneous Immunoglobulin Gammanorm on the Distribution of IgG Subclasses and on Immunity of Patients With Secondary Immunodeficiency

CompletedNCT03369301

OctapharmaSecondary Immune Deficiency

Start: 2017-09-25End: 2019-11-22Updated: 2022-03-02

Trial Assessing Safety and Efficacy of Gammanorm® in Autoimmune Diseases

TerminatedNCT03656640

OctapharmaAutoimmune Diseases

Start: 2016-11-23End: 2019-12-09Updated: 2021-03-10

Related Papers

Rapid Push vs Pump-Infused Subcutaneous Immunoglobulin Treatment: a Randomized Crossover Study of Quality of Life in Primary Immunodeficiency Patients.

2018-05-3115 citations